tbuckley/cabot-search huggingface dataset:
Islet Transplantation Is Associated With an Improvement of Cardiovascular Function in Type 1 Diabetic Kidney Transplant Patients
Authors: Paolo Fiorina, Chiara Gremizzi, Paola Maffi, Rossana Caldara, Davide Tavano, Lucilla Monti, Carlo Socci, Franco Folli, Ferruccio Fazio, Ettore Astorri, Alessandro Del Maschio, Antonio Secchi
Journal: Diabetes Care (2005)

Cardiovascular mortality and morbidity are major problems in type 1 diabetic patients with end-stage renal disease (ESRD). The aim of this study was to determine whether islet transplantation can improve cardiovascular function in these patients.We assessed various markers of cardiac function at baseline and 3 years later in a population of 42 type 1 diabetic patients with ESRD who received a kidney transplant. Seventeen patients then received an islet transplant that had persistent function as defined by long-term C-peptide secretion (kidney-islet group). Twenty-five patients did not receive a functioning islet transplant (kidney-only group).GHb levels were similar in the two groups, whereas the exogenous insulin requirement was lower in the kidney-islet group with persistent C-peptide secretion. Overall, cardiovascular parameters improved in the kidney-islet group, but not in the kidney-only group, with an improvement of ejection fraction (from 68.2 +/- 3.5% at baseline to 74.9 +/- 2.1% at 3 years posttransplantation, P < 0.05) and peak filling rate in end-diastolic volume (EDV) per second (from 3.87 +/- 0.25 to 4.20 +/- 0.37 EDV/s, P < 0.05). Time to peak filling rate remained stable in the kidney-islet group but worsened in the kidney-only group (P < 0.05). The kidney-islet group also showed a reduction of both QT dispersion (53.5 +/- 4.9 to 44.6 +/- 2.9 ms, P < 0.05) and corrected QT (QTc) dispersion (67.3 +/- 8.3 to 57.2 +/- 4.6 ms, P < 0.05) with higher erythrocytes Na(+)-K(+)-ATPase activity. In the kidney-islet group only, both atrial natriuretic peptide and brain natriuretic peptide levels decreased during the follow-up, with a stabilization of intima-media thickness.Our study showed that type 1 diabetic ESRD patients receiving a kidney transplant and a functioning islet transplant showed an improvement of cardiovascular function for up to 3 years of follow-up compared with the kidney-only group, who experienced an early failure of the islet graft or did not receive an islet graft.
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
Authors: R Silvennoinen, T Lundan, V Kairisto, T-T Pelliniemi, M Putkonen, P Anttila, V Huotari, P Mäntymaa, S Siitonen, L Uotila, T-L Penttilä, V Juvonen, T Selander, K Remes
Journal: Blood Cancer Journal (2014)

Multiparameter flow cytometry (MFC) and allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) are the two most sensitive methods to detect minimal residual disease (MRD) in multiple myeloma (MM). We compared these methods in 129 paired post-therapy samples from 22 unselected, consecutive MM patients in complete/near complete remission. Appropriate immunophenotypic and ASO RQ-PCR-MRD targets could be detected and MRD analyses constructed for all patients. The high PCR coverage could be achieved by gradual widening of the primer sets used for clonality detection. In addition, for 13 (55%) of the patients, reverse orientation of the ASO primer and individual design of the TaqMan probe improved the sensitivity and specificity of ASO RQ-PCR analysis. A significant nonlinear correlation prevailed between MFC-MRD and PCR-MRD when both were positive. Discordance between the methods was found in 32 (35%) paired samples, which were negative by MFC-MRD, but positive by ASO RQ-PCR. The findings suggest that with the described technique, ASO RQ-PCR can be constructed for all patients with MM. ASO RQ-PCR is slightly more sensitive in MRD detection than 6−10-color flow cytometry. Owing to technical demands ASO RQ-PCR could be reserved for patients in immunophenotypic remission, especially in efficacy comparisons between different drugs and treatment modalities.
Unreported Financial Disclosures in a Study of Migraine and Cardiovascular Disease
Authors: Tobias Kurth, J. Michael Gaziano, Nancy R. Cook, Giancarlo Logroscino, Hans-Christoph Diener, Julie E. Buring
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)
Authors: Pranesh K. Chakraborty, Klaus Schmitz-Abe, Erin K. Kennedy, Hapsatou Mamady, Turaya Naas, Danielle Durie, Dean R. Campagna, Ashley Lau, Anoop K. Sendamarai, Daniel H. Wiseman, Alison May, Stephen Jolles, Philip Connor, Colin Powell, Matthew M. Heeney, Patricia-Jane Giardina, Robert J. Klaassen, Caroline Kannengiesser, Isabelle Thuret, Alexis A. Thompson, Laura Marques, Stephen Hughes, Denise K. Bonney, Sylvia S. Bottomley, Robert F. Wynn, Ronald M. Laxer, Caterina P. Minniti, John Moppett, Victoria Bordon, Michael Geraghty, Paul B. M. Joyce, Kyriacos Markianos, Adam D. Rudner, Martin Holcik, Mark D. Fleming
Journal: Blood (2014)
Adverse drug reaction cards carried by patients.
Authors: P C Hannaford
Journal: BMJ (1986)

Five hundred patients were asked whether they were allergic to any medicines. The description given of any stated reaction was assessed to see whether an important adverse drug reaction was likely to have occurred. The patients' records were also examined for collaborative evidence. Poor documentation often made it difficult to confirm the patient's claim of drug sensitivity. A total of 89 patients may have suffered from important adverse reactions to 113 drugs. Full documentation of adverse reactions is important, but only eight patients carried any information to warn others of their sensitivities. Patients should be asked about any drug sensitivities and, if appropriate, given written confirmation of them. A quick, simple method of doing this would be to provide patients' with a plastic card, similar to a credit card, with instructions and details of the reaction written on it with an indelible pen.
Zika virus infection complicated by Guillain-Barré syndrome – case report, French Polynesia, December 2013
Authors: E Oehler, L Watrin, P Larre, I Leparc-Goffart, S Lastère, F Valour, L Baudouin, H P Mallet, D Musso, F Ghawche
Journal: Eurosurveillance (2014)

Binary file ES_Abstracts_Final_ECDC.txt matches
Anemia in Low-Income Children
Authors: Sandra M. Stewart-Pinkham
Journal: JAMA (1988)

<h3>To the Editor.</h3> —Regarding the article by Yip et al<sup>1</sup>on the declining prevalence of anemia, I believe it is important to recognize that a decline in lead exposure from leaded gasoline occurred during the same time period, reflected in a significant decrease in blood lead levels. Lead is an antimetabolite of copper, essential for the utilization of iron. This decreased exposure is a factor that would affect all socioeconomic groups. Although there is decreased exposure to lead, there is increasing exposure to cadmium. Cadmium rarely causes anemia, but it does cause intravascular hemolysis and increased osmotic fragility. The hematocrit may be on the low side of normal. Because cadmium in the gastrointestinal tract blocks the uptake of vitamin B<sub>12</sub>, mild macrocytosis may be seen as well as a slight increase in reticulocytes and a slight decrease in the red blood cell count. The Special Supplemental Food Program
Abstract 2869: Interaction between a COX2 polymorphism and ER status in relation to risk for early events in breast cancer patients.
Authors: Andrea Markkula, Maria Simonsson, Christian Ingvar, Carsten Rose, Helena C. Jernström
Journal: Cancer Research (2013)

Abstract Background. Cyclooxygenase-2 (COX2) polymorphisms are associated with cancer in the lung, colorectum, and breast. In several studies, the COX2 rs5277 variant has been implicated in cancers associated with inflammation. COX-2 is the rate-limiting enzyme in the production of the pro-inflammatory prostaglandin, which activates CYP19 transcription and increases CYP19 (aromatase) levels, the key enzyme in androgen to estrogen conversion. The aim of this study was to investigate whether associations between the COX2 rs5277 polymorphism and early breast cancer events vary according to ER-status. Methods. COX2 rs5277 (306G&amp;gt;C, V102V) was genotyped with PCR based methods in 634 breast cancer patients in a population-based ongoing cohort from southern Sweden. Clinical data were obtained from patient charts and pathology reports. Rs5277 was examined in relation to patient, tumor characteristics and early events. Results. Minor allele frequency was 16.1%. Rs5277 was not associated with patient or tumor characteristics. Median follow-up was 4.92 years in patients with invasive tumors. Overall, increasing number of C-alleles was not associated with early events (Log Rank 1df; p=0.35). However, after stratification according to ER status, increasing number of C-alleles was associated with a fewer early events in the 73 patients with ER-negative tumors (Log Rank 1df; p=0.029) and borderline associated with more early events among the among the 497 patients with ER-positive tumors (Log Rank 1df; p=0.081). The interaction between ER-status and COX2 rs5277 on early events was significant (pinteraction=0.010). In a multivariate model among patients with ER-positive tumors, a CC genotype predicted an increased risk for early events (HR 4.25; 95 %CI 1.18-15.29; p=0.027), adjusted for tumor size (pT), nodal involvement, age, and histological grade. None of the patients with a CC genotype and an ER-negative tumor had a breast cancer event during the follow-up. Conclusion. The results indicate that the association between the COX2 rs5277 polymorphism and early breast cancer events varies according to ER-status. Information on rs5277 genotype may provide additional prognostic information for individual breast cancer patients. Citation Format: Andrea Markkula, Maria Simonsson, Christian Ingvar, Carsten Rose, Helena C. Jernström. Interaction between a COX2 polymorphism and ER status in relation to risk for early events in breast cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2869. doi:10.1158/1538-7445.AM2013-2869
The Treatment of Recurrent Corneal Erosion
Authors: Joel Sugar
Journal: JAMA (1987)

<h3>To the Editor.—</h3> Dr Lerman,<sup>1</sup>in his answer in response to a query on the treatment of recurrent corneal erosion, states that "the treatment... is still far from definitive." While this is indeed true, many ophthalmologists would take a therapeutic approach different from the one recommended by Dr Lerman. The standard treatment for recurrent corneal erosions is patching at the time of the erosion and the use of topical ointments, especially hypertonic saline ointment, at bedtime to prevent recurrent erosions. When this treatment is not successful, débridement of the loose corneal epithelium followed by patching may allow new epithelium to lay down normal basement membrane, eliminating future erosions. When all of these treatments fail, the use of soft contact lenses or of anterior stromal puncture to allow subepithelial scarring to hold the epithelium in place may be beneficial.<sup>2</sup>In general, the use of topical corticosteroids or pyrimidine analogues
Abstract 4574: FGFR1 amplification in high grade, estrogene receptor positive and metastasized breast cancers
Authors: Katrin Pfaltz, Sandra Schneider, Uwe Güth, Ergin Kilic, Serenella Eppenberger-Castori, Coya F. Tapia
Journal: Cancer Research (2012)

Abstract Background: The FGFR1-gene (fibroblast growth factor receptor 1) is located at chromosome 8p12 encoding for a tyrosine kinase. FGFR1 is involved in cell cycle, differentiation, survival, apoptosis, and angiogenesis. Recently, it was shown that breast cancer cell lines harboring a FGFR1 amplification were more sensitive to treatment with an FGFR inhibitor. To estimate if FGFR inhibitors can be a therapeutic option in human breast cancer we investigated the prevalence and the histological subtypes of FGFR1 amplification in a large cohort of breast cancers. Methods: Tissue micro-arrays with 907 breast cancers were hybridized using the commercially available fluorescent in-situ hybridization probe (FGFR1/CEN8; ZytoVision®). The results were interpreted as following: a normal gene status was considered as a ratio (FGFR1/CEN8): 0.8-1.9, an amplification was defined as a ratio β2.0, a polysomy was defined as more than &amp;gt;4 FGFR1 and CEP8 signals. Results: FGFR1 amplification was observed in 8.9% (n=81), a normal gene status was found in 80.7% (n=732), and a polysomy was detected in 10.2% (n=93) tumors. FGFR1 amplified breast cancers showed the following features: expression of estrogen receptor 85% (67/78), ductal 72.8% (59/81), high grade (G3) 45.5% (35/77), her2 over-expression (score2+/3+) 16% (12/75), and 18% (13/72) recurrence. Comparing T (T1, T2, T3) and N (N0 and &amp;gt;N0)-categories between FGFR1 amplified and non-amplified tumors the following results were seen: T1: 25% (19/77) vs. 34% (245/719), T2: 56% (43/77) vs. 48% (345/719), T3: 9% (7/77) vs. 6% (43/719), N0: 44.5% (28/63) vs 53% (338/641), &amp;gt;N0: 55.5% (35/63) vs 47% (303/641). We could observe a slight better long term overall survival in patients treated with anti-hormonal therapy and FGFR1 amplified breast cancers (p=0.085). Conclusions: FGFR1 amplification is prevalent (8.9%) in breast cancer, especially among the most frequent subtypes such as estrogen receptor positive breast cancers (10%) and ductal type (8%). Further, FGFR1 amplified breast cancer showed often unfavorable/aggressive features such as a high tumor grade (45.5%), larger tumor diameter, and metastasis (55.5%). These patients are a clinically relevant group since they need aggressive adjuvant treatment regimen. The detection of FGFR1 amplification could help in the identification of some patients already at higher risk which might benefit from a new therapeutic option with FGFR1 inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4574. doi:1538-7445.AM2012-4574
Hepatitis C virus dynamicsin vivo: Effect of ribavirin and interferon alfa on viral turnover
Authors: Stefan Zeuzem, Jürgen M. Schmidt, Jung-hun Lee, Michael von Wagner, Gerlinde Teuber, Kurt W. Roth
Journal: Hepatology (1998)

Treatment of patients with chronic hepatitis C with recombinant interferon alfa (rIFN-α) can cause a decrease of serum transaminases and hepatitis C virus (HCV) RNA. Recent trials evaluating combination therapy of IFN-α and ribavirin suggested a potential synergistic effect. From serial measurements of serum HCV RNA concentrations following treatment-induced perturbation of the balance between virus production and clearance, we compared the antiviral efficacy of both IFN-α alone and IFN-α in combination with ribavirin. Chronically HCV-infected patients were treated with either 3 × 3 MU or 3 × 6 MU rIFN-α per week or 3 × 6 MU rIFN-α plus 14 mg/kg of body weight ribavirin per day. The time-dependent HCV RNA concentrations during antiviral treatment were analyzed by iterative least-squares regression. After initiation of antiviral therapy, HCV RNA declined exponentially below the detection limit of the reverse-transcription polymerase chain reaction assay (1,000 HCV RNA molecules per milliliter) in 10 of 26 (39%), 10 of 19 (53%), and 10 of 18 patients (56%) treated with 3 × 3 MU, 3 × 6 MU rIFN-α without and with ribavirin, respectively. Viral clearance from serum was faster in patients treated with 3 × 6 MU rIFN-α ( t 1/2 = 0.23 ± 0.15) compared with patients treated with 3 × 3 MU rIFN-α per week (0.67 ± 0.36 days) ( P &lt; .004). However, half-lives of viral clearance were similar in patients treated with rIFN-α or rIFN-α plus ribavirin. For virus release from infected hepatocytes, absence and presence of ribavirin yielded half-lives of t 1/2 = 2.54 ± 2.10 and t 1/2 = 1.99 ± 1.70, respectively, indicating that ribavirin does not significantly inhibit HCV production. In conclusion, the data of the present study indicate that higher rIFN-α doses accelerate viral clearance from serum. Ribavirin (14 mg/kg/d), however, lacks synergistic antiviral effects in the treatment of chronic hepatitis C with 3 × 6 MU rIFN-α per week.
The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90
Authors: Chenhui Wang, Ling Wu, Katarzyna Bulek, Bradley N Martin, Jarod A Zepp, Zizhen Kang, Caini Liu, Tomasz Herjan, Saurav Misra, Julie A Carman, Ji Gao, Ashok Dongre, Shujie Han, Kevin D Bunting, Jennifer S Ko, Hui Xiao, Vijay K Kuchroo, Wenjun Ouyang, Xiaoxia Li
Journal: Nature Immunology (2012)
Health ministers pledge to tackle non-communicable diseases with global action
Authors: R. Smith
Journal: BMJ (2011)

Ninety health ministers and health officials from 167 countries committed themselves to taking “whole of government” and international actions to combat non-communicable disease (NCDs) at a meeting in Moscow last week. 

They gathered at the First Global Ministerial Conference on Healthy Lifestyles and Non-communicable Disease Control, which is part of the build up to the United Nations High Level Meeting on NCDs to be held in New York in September. This will be only the second such UN meeting on health; the first, in 2001, gave rise to the Global Fund for AIDS, TB, and Malaria.

NCDs were left out of the Millennium Development Goals, but pressure for global action has been growing steadily. Margaret Chan, director general of WHO, said, “For some countries it is no exaggeration to describe the situation as an impending disaster. I mean a disaster for …
Coronary heart disease in women
Authors: Ghada W Mikhail
Journal: BMJ (2005)

Is underdiagnosed, undertreated, and under-researched 

Coronary heart disease remains the leading cause of death in men and women worldwide, and cardiovascular deaths exceed the number of deaths from all cancers combined. In the United Kingdom, coronary heart disease causes almost 114 000 deaths a year, and one in six occurs in women.1 In the UK and Europe, one woman dies every six minutes of heart disease and in the United States, one every minute. Moreover, in Europe, cardiovascular disease kills a higher percentage of women (55%) than men (43%).2 Yet coronary heart disease is still considered a disease of men.

Many women are unaware that coronary heart disease is their main killer; their biggest fear is breast cancer. Even more worrying, however, is the apparent lack of awareness of cardiovascular disease in women among healthcare professionals. At the time of presentation with heart disease, women tend to be 10 years older than men, and at the time of their first myocardial infarction they are usually …
Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis
Authors: Philip Hilgard, Thomas Schreiter, Richard J. Stockert, Guido Gerken, Ulrich Treichel
Journal: Hepatology (2004)

Hemolysis in patients with advanced alcoholic liver disease is a common clinical problem and indicates an unfavorable prognosis. In many cases, the etiology of the hemolysis remains unknown. We observed three patients with alcoholic liver disease, suffering from severe hemolytic anemia, requiring multiple blood transfusions. Steroid therapy was ineffective and two of the patients died. All patients had a soluble variant of the human asialoglycoprotein receptor (s-ASGP-R) in their serum, as well as high titers of autoantibodies against this receptor (anti-ASGP-R). Consecutively, examination of 60 patients with alcoholic liver disease revealed a high incidence for s-ASGP-R (36%) and anti-ASGP-R (27%) in patients with alcoholic liver cirrhosis (ALC) compared to patients with cirrhosis due to viral hepatitis. The potential etiology of hemolysis was studied in vitro on erythrocytes from patients with ALC and from healthy donors. Isolated ASGP-R but not anti-ASGP-R bound to the surface of erythrocytes preferentially of blood group A1 and caused dose-dependent agglutination and hemolysis, while this phenomenon was much lower using erythrocytes of the blood group B and almost absent with blood group O-erythrocytes. Furthermore, agglutination and hemolysis only occurred in erythrocytes from ALC-patients or after the pre-treatment of cells with neuraminidase. ASGP-R induced agglutination and hemolysis was blocked by the competitive ASGP-R inhibitor asialofetuin. In conclusion, our results indicate a new, non-immunological mechanism for hemolysis in patients with alcoholic liver disease, mediated through agglutination by a soluble variant of the human asialoglycoprotein receptor and mechanical shear stress.
A Novel Bovine Virus Efficiently Transduces Inner Ear Neuroepithelial Cells
Authors: Giovanni Di Pasquale, Agnieszka Rzadzinska, Mark E. Schneider, Ioannis Bossis, John A. Chiorini, Bechara Kachar
Journal: Molecular Therapy (2005)

Disruption of the cellular composition or arrangement of the sensory epithelia due to hair cell or supporting cell damage leads to hearing loss and vestibular dysfunctions. These peripheral hearing disorders make good targets for gene therapy; however, development requires efficient gene transfer methods for the inner ear. Here we characterized the cellular tropism of a novel adeno-associated bovine virus vector (BAAV) in cultured rat inner ear epithelia. To help identify transduced cells, we used beta-actin-GFP as a reporter gene. We found that BAAV efficiently transduced auditory and vestibular hair cells as well as all types of supporting cells with no apparent pathological effects. The number of transduced hair cells significantly increased in both a dose- and a time-dependent manner. Transduction was independent of the cells' maturation state and was observed in both P2 and P10 cultures. Interestingly, even after several days of incubation with BAAV, hair cells demonstrated varying progression of beta-actin-GFP incorporation into the stereocilia. This suggests that the onset of viral transduction can occur throughout the course of the experiment. Of the other tested AAVs, AAV2 and AAV5 transduced only a small percentage of inner and vestibular hair cells, respectively, whereas no transduction was detected with AAV4.